Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
Status:
Recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
This is a prospective single arm phase II study, and the purpose of this study is to evaluate
the efficiency of R2 regimen (rituximab & lenalidomide) combined with intravitreal
methotrexate and followed by lenalidomide maintenance in newly-diagnosed primary intraocular
lymphoma. Progression free survival (PFS) of the cohort is the primary endpoint.